Contrasting Amarillo Biosciences (OTCMKTS:AMAR) and Nektar Therapeutics (OTCMKTS:NKTR)

Share on StockTwits

Amarillo Biosciences (OTCMKTS:AMAR) and Nektar Therapeutics (NASDAQ:NKTR) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, risk, institutional ownership and earnings.

Earnings & Valuation

This table compares Amarillo Biosciences and Nektar Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Amarillo Biosciences $80,000.00 196.05 -$1.34 million N/A N/A
Nektar Therapeutics $1.19 billion 4.21 $681.31 million $3.78 7.62

Nektar Therapeutics has higher revenue and earnings than Amarillo Biosciences.

Risk & Volatility

Amarillo Biosciences has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 2.68, suggesting that its stock price is 168% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Amarillo Biosciences and Nektar Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amarillo Biosciences 0 0 0 0 N/A
Nektar Therapeutics 0 2 8 0 2.80

Nektar Therapeutics has a consensus price target of $71.33, indicating a potential upside of 147.69%. Given Nektar Therapeutics’ higher probable upside, analysts clearly believe Nektar Therapeutics is more favorable than Amarillo Biosciences.

Insider and Institutional Ownership

92.1% of Nektar Therapeutics shares are held by institutional investors. 4.0% of Nektar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Amarillo Biosciences and Nektar Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Amarillo Biosciences N/A -224.04% -104.42%
Nektar Therapeutics 55.65% 37.63% 29.67%

Summary

Nektar Therapeutics beats Amarillo Biosciences on 10 of the 11 factors compared between the two stocks.

About Amarillo Biosciences

Amarillo Biosciences, Inc. engages in the development of biologics for the treatment of human and animal diseases. The company owns or licenses five issued patents related to the low-dose oral delivery of interferon; and owns one issued patent on its dietary supplement, Maxisal. It focuses on research for the treatment of human disease indications primarily influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon alpha. Amarillo Biosciences, Inc. was founded in 1984 and is based in Amarillo, Texas.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology. It also develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor agonist that is in Phase I for solid tumors; and NKTR-255, which is in preclinical stage for immuno-oncology. In addition, the is developing ADYNOVATE and ADYNOVI for hemophilia A; MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; CIMZIA for crohn's disease, rheumatoid arthritis, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia associated with chronic kidney disease. Further, it is developing Macugen for age-related macular degeneration; Somavert for acromegaly; Neulasta for neutropenia; Dapirolizumab Pegol for systemic lupus erythematosus; PEGPH20 for pancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Halozyme Therapeutics, Inc.; Bristol-Myers Squibb Company; Baxalta Incorporated; and Eli Lilly and Company, as well as with Merck KGaA and Pfizer Inc to develop a therapy for treating pancreatic cancer. Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, California.

Receive News & Ratings for Amarillo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarillo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Critical Comparison: Energy Transfer LP Unit  versus Southcross Energy Partners
Critical Comparison: Energy Transfer LP Unit versus Southcross Energy Partners
Parsons  & Cerner  Head to Head Contrast
Parsons & Cerner Head to Head Contrast
Contrasting Masimo  and Newcardio
Contrasting Masimo and Newcardio
SolarWinds  and MAM Software Group  Financial Comparison
SolarWinds and MAM Software Group Financial Comparison
Piedmont Lithium  & Its Peers Financial Review
Piedmont Lithium & Its Peers Financial Review
Analyzing Hudson Global  and The Competition
Analyzing Hudson Global and The Competition


© 2006-2019 Ticker Report